«This could be a universal mechanism for enhancing
efficacy of immunotherapies in glioma,» she says.
Our objective is to use our microbiome therapeutic approach to improve
the efficacy of immunotherapy in patients with life - threatening cancers.»
Not exact matches
Now,
immunotherapy — a type
of treatment that harnesses the patient's immune system to combat the disease — represents the future
of cancer treatment, with its
efficacy being demonstrated
in even the most aggressive types
of cancer.
Schlom,
of the National Cancer Institute, says the next challenge for researchers is to find ways to combine different
immunotherapy drugs into single treatments and measure their
efficacy in clinical trials.
In a phase 1b clinical trial with 21 patients, researchers tested the safety and
efficacy of combining the
immunotherapy drug pembrolizumab with an oncolytic virus called T - VEC.
Dr. Gnjatic's research focuses on human antigen - specific immune responses to tumor antigens,
in an attempt to define new targets for the development
of cancer
immunotherapies, assess the
efficacy of these
immunotherapies, and learn why they may fail.
«Our work has shown that overcoming brain tumor - induced immune suppression is critical for enhancing
efficacy of anti-tumor
immunotherapies,» says first author Neha Kamran, Ph.D., a U-M neurosurgery research fellow
in the Castro / Lowenstein Lab.
«As we identify which bacteria have a similar effect
in humans, it should be possible to develop probiotic supplements that specifically improve
efficacy of immunotherapies,» he says.
The full paper that this statement is
in response to can be found at: Niederberger et al. 2018 Safety and
efficacy of immunotherapy with the recombinant B - cell epitope — based grass pollen vaccine BM32.
In the ensuing months, the two companies have published detailed, promising animal studies of their immunotherapies, including preclinical efficacy studies in animal models of human synucleinopathie
In the ensuing months, the two companies have published detailed, promising animal studies
of their
immunotherapies, including preclinical
efficacy studies
in animal models of human synucleinopathie
in animal models
of human synucleinopathies.
A range
of immunotherapies are currently
in use, yet their
efficacy can be varied and differ from patient to patient.
Immune Design entered into a clinical trial collaboration with Genentech, a member
of the Roche Group, to evaluate the safety and
efficacy of its CMB305 cancer
immunotherapy product candidate combined with the investigational cancer
immunotherapy atezolizumab
in a randomized Phase 2 trial
in patients with soft tissue sarcoma.